Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb Predictors of Response to Linaclotide in Irritable Bowel Syndrome
2013-001248-67Phase 3Active
- Sponsor
- Almirall
- Start
- Nov 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, single-arm trial of linaclotide in irritable bowel syndrome (IBS), sponsored by Almirall. Primary endpoint: Clinical response at 12 weeks. Started Nov 2013; status: active.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2013-001248-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001248-67.